NYSE:OGN Organon & Co. Q1 2026 Earnings Report $13.42 -0.04 (-0.26%) Closing price 03:59 PM EasternExtended Trading$13.42 -0.01 (-0.04%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Organon & Co. EPS ResultsActual EPS$0.71Consensus EPS $0.83Beat/MissMissed by -$0.12One Year Ago EPS$1.02Organon & Co. Revenue ResultsActual Revenue$1.46 billionExpected Revenue$1.49 billionBeat/MissMissed by -$27.54 millionYoY Revenue Growth-3.50%Organon & Co. Announcement DetailsQuarterQ1 2026Date4/30/2026TimeBefore Market OpensConference Call DateThursday, April 30, 2026Conference Call Time7:00AM ETUpcoming EarningsOrganon & Co.'s Q2 2026 earnings is estimated for Tuesday, August 4, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Organon & Co. Earnings HeadlinesHanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast AsiaMay 21 at 5:06 AM | globenewswire.comOrganon & Co. (NYSE:OGN) Receives $11.40 Average Price Target from AnalystsMay 21 at 3:33 AM | americanbankingnews.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 21 at 1:00 AM | Paradigm Press (Ad)Deep value mid-caps: 10 names trading at single-digit forward P/EsMay 18 at 9:07 AM | seekingalpha.comOrganon to Present New Research on Access and Value at ISPOR 2026May 15, 2026 | businesswire.comOrganon Buyout By Sun Pharma Shifts Focus To Cash Value And TimingMay 8, 2026 | finance.yahoo.comSee More Organon & Co. Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Organon & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Organon & Co. and other key companies, straight to your email. Email Address About Organon & Co.Organon & Co. (NYSE:OGN) is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co. in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact. In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies. The company’s offerings extend to emerging areas such as endometriosis and osteoporosis, underscoring its commitment to advancing care for women throughout various life stages. This specialized focus leverages decades of research and clinical experience inherited from its predecessor organization. Organon’s biosimilars division develops and markets lower-cost versions of complex biologic therapies. Its pipeline includes multiple biosimilar candidates designed to increase patient access to treatments for autoimmune disorders and other serious conditions. By combining in-house development capabilities with strategic partnerships, Organon aims to build a sustainable biosimilars business that complements its branded product lines. With operations spanning more than 140 countries, Organon serves diverse markets across North America, Europe, Latin America, Asia and emerging regions. The company is led by President and Chief Executive Officer Kevin Ali, who oversees global strategy and operations. Organon’s corporate vision emphasizes innovation, patient-centricity and the responsible stewardship of its legacy products to drive long-term growth and healthcare advancement. View Organon & Co. ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingTarget Shows Strengths, But Analysts Want to See MoreFreight Boom: The Hormuz Blockade PaydayTJX Companies Fires on All Cylinders With 9% Revenue GrowthAnalog Devices Provides Much-Needed Pullback: How Low Can It Go?USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
